Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 6/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26683550 | 1.00 | DDB1 (0.40) | DDB1CRBNMEN1KMT2AGAA | |
| SCHEMBL26683917 | 0.88 | CRBN (0.41) | DDB1CRBNMEN1KMT2AGAA | |
| SCHEMBL26683846 | 0.87 | LMNA (0.46) | DDB1CRBNMEN1KMT2AALDH1A1 | |
| Formic Acid SCHEMBL25427314 | 0.84 | DDB1 (0.38) | DDB1CRBNMEN1KMT2AGAA | |
| Formic Acid SCHEMBL29507041 | 0.84 | DDB1 (0.38) | DDB1CRBNMEN1KMT2AGAA | |
| SCHEMBL26842027 | 0.83 | DDB1 (0.44) | DDB1CRBNGAASMN1; SMN2GPR119 | |
| SCHEMBL26684246 | 0.81 | GPR119 (0.43) | DDB1CRBNSMN1; SMN2GPR119 | |
| SCHEMBL30688284 | 0.81 | GPR119 (0.43) | DDB1CRBNSMN1; SMN2GPR119 | |
| SCHEMBL26683558 | 0.78 | PLG (0.40) | DDB1CRBNMEN1KMT2AGAA | |
| SCHEMBL26683618 | 0.73 | CRBN (0.41) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | DDB1 4162/4885CRBN 2312/4885MEN1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.